At one time Geron was a company that everyone was watching primarily due to their stem cell research and trials for patients with spinal cord injuries. Almost a year ago they discontinued their stem cell research to place all their efforts into cancer research and this is the first zero to appear sadly.
Geron To Focus on Cancer Programs Discontinues Internal Development of Spinal Stem Cell Programs-66 Jobs Go Away–Biotech Gets Shot in the Foot With Funding While the Ridiculously Valued Chase for Social Algorithms Intensifies
You can review a back link below for some history as the program was on and then it was off and then it was back on again, all over the use of embryonic stem cells being used. The clinical trials are still working in the spinal cord area in Switzerland, but not much in the US other than the first couple of enrolled patients. Stanford University was also in on the trials.
Geron stopped the mid-stage breast cancer trial after an interim check showed that the drug imetelstat was not better than the current recommended treatment in extending patients' lives without the disease progressing.
While an interim analysis of the company's non small-cell lung cancer (NSCLC) study supported a modest benefit from the drug, Geron said it was doubtful about starting late-stage trials for the indication.
"These are two of their big opportunities gone away," Needham & Co analyst Chad Messer said. "The problem looks like some cross-toxicity between imetelstat and paclitaxel."
An internal review revealed that more patients given a combination of imetelstat and paclitaxel, an approved chemotherapy drug, were dying or discontinuing treatment, compared with those administered only paclitaxel.